Ph3 study of sacituzumab with pembro in patients with cervical cancer (GOG-3123)

MK2870-036: A Phase 3 Randomized Open-label Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as First-line Maintenance Treatment for Participants With Persistent Recurrent or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse 036/GOG-3123/ENGOT-cx22)